139 related articles for article (PubMed ID: 22392486)
1. Association between endometriosis and polymorphisms in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptor and osteoprotegerin genes and their serum levels.
Kim H; Ku SY; Suh CS; Kim SH; Kim JH; Kim JG
Arch Gynecol Obstet; 2012 Jul; 286(1):147-53. PubMed ID: 22392486
[TBL] [Abstract][Full Text] [Related]
2. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis.
Harada M; Osuga Y; Hirata T; Hirota Y; Koga K; Yoshino O; Morimoto C; Fujiwara T; Momoeda M; Yano T; Tsutsumi O; Taketani Y
Hum Reprod; 2004 Oct; 19(10):2188-91. PubMed ID: 15242994
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in the tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) do not contribute but Death Receptor (DR4) genes may contribute to susceptibility to head and neck cancer in Pakistani population.
Sarwar R; Mansoor Q; Farooqi AA; Shahzad S; Fayyaz S; Ismail M
Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):53-6. PubMed ID: 26718429
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand and death receptor genes contribute to susceptibility to bladder cancer.
Timirci-Kahraman O; Ozkan NE; Turan S; Farooqi AA; Verim L; Ozturk T; Inal-Gultekin G; Isbir T; Ozturk O; Yaylim I
Genet Test Mol Biomarkers; 2015 Jun; 19(6):309-15. PubMed ID: 25955868
[TBL] [Abstract][Full Text] [Related]
5. Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels.
Verim A; Turan S; Farooqi AA; Kahraman OT; Tepe-Karaca C; Yildiz Y; Naiboglu B; Ozkan NE; Ergen A; Isitmangil GA; Yaylim I
Asian Pac J Cancer Prev; 2014; 15(24):10697-703. PubMed ID: 25605161
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells.
Miyashita T; Kawakami A; Nakashima T; Yamasaki S; Tamai M; Tanaka F; Kamachi M; Ida H; Migita K; Origuchi T; Nakao K; Eguchi K
Clin Exp Immunol; 2004 Aug; 137(2):430-6. PubMed ID: 15270863
[TBL] [Abstract][Full Text] [Related]
7. The Impact of TRAIL (C1595T and G1525A) and DR4 (rs20576) Gene Polymorphisms on Systemic Lupus Erythematosus.
Sandoughi M; Salimi S; Shahraki-Ghadimi H; Saravani M
Biochem Genet; 2020 Aug; 58(4):649-659. PubMed ID: 32342239
[TBL] [Abstract][Full Text] [Related]
8. Association of TRAIL and Its Receptors with Large-Artery Atherosclerotic Stroke.
Pan X; Pang M; Ma A; Wang K; Zhang Z; Zhong Q; Yang S
PLoS One; 2015; 10(9):e0136414. PubMed ID: 26334877
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin, trail and osteoprotegerin/trail ratio in patients at early phase of acute pancreatitis.
Dumnicka P; Zylka A; Kusnierz-Cabala B; Gurda-Duda A; Kuzniewski M; Drozdz R; Kulig J
Folia Med Cracov; 2014; 54(2):17-26. PubMed ID: 25648306
[TBL] [Abstract][Full Text] [Related]
11. Enhanced extrinsic apoptosis of therapy-induced senescent cancer cells using a death receptor 5 (DR5) selective agonist.
Soto-Gamez A; Wang Y; Zhou X; Seras L; Quax W; Demaria M
Cancer Lett; 2022 Jan; 525():67-75. PubMed ID: 34728311
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between osteoprotegerin gene 209G/A, 245T/G and 1181G/C polymorphism and acute coronary syndromes in Han people of Fujian area].
Luo ZR; Xie QJ
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Dec; 24(12):730-3. PubMed ID: 23168201
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor (TNF)-TNF receptor gene polymorphisms and their serum levels in Korean women with endometriosis.
Chae SJ; Kim H; Jee BC; Suh CS; Kim SH; Kim JG
Am J Reprod Immunol; 2008 Nov; 60(5):432-9. PubMed ID: 19238748
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling and cell death in the immature central nervous system after hypoxia-ischemia and inflammation.
Kichev A; Rousset CI; Baburamani AA; Levison SW; Wood TL; Gressens P; Thornton C; Hagberg H
J Biol Chem; 2014 Mar; 289(13):9430-9. PubMed ID: 24509861
[TBL] [Abstract][Full Text] [Related]
16. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort.
Audo R; Daien C; Papon L; Lukas C; Vittecoq O; Hahne M; Combe B; Morel J
Arthritis Res Ther; 2015 Jul; 17(1):193. PubMed ID: 26220665
[TBL] [Abstract][Full Text] [Related]
18. Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: An observational study.
Moon AR; Park Y; Chang JH; Lee SS
Medicine (Baltimore); 2019 Mar; 98(10):e14489. PubMed ID: 30855435
[TBL] [Abstract][Full Text] [Related]
19. The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?
Castellino G; Corallini F; Bortoluzzi A; La Corte R; Lo Monaco A; Secchiero P; Zauli G; Trotta F
Rheumatology (Oxford); 2010 Jun; 49(6):1173-6. PubMed ID: 20299382
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
Emery JG; McDonnell P; Burke MB; Deen KC; Lyn S; Silverman C; Dul E; Appelbaum ER; Eichman C; DiPrinzio R; Dodds RA; James IE; Rosenberg M; Lee JC; Young PR
J Biol Chem; 1998 Jun; 273(23):14363-7. PubMed ID: 9603945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
